Zobrazeno 1 - 5
of 5
pro vyhledávání: '"John Villano"'
Autor:
Deborah Schrag, Hajime Uno, Rachel Rosovsky, Cynthia Rutherford, Kristen Sanfilippo, John Villano, Monic Drescher, Nagesh Jayaram, Chris Holmes, Lawerence Feldman, Ottavia Zattra1, Haley Farrar-Muir1, Christine Cronin, Ethan Basch, Anna Weiss, Jean Connors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcfcfe2b17b593ff13d574d94bc51521
https://doi.org/10.25302/01.2023.cer.150329805
https://doi.org/10.25302/01.2023.cer.150329805
Abstract CT221: Phase II of frontline maintenance rucaparib in combination with nivolumab in ES SCLC
Autor:
Aman Chauhan, Jill Kolesar, Donglin Yan, Zhonglin Hao, Ronald McGarry, John Villano, Ralph Zinner, Ashish Maskey, Jordan Miller, Timothy Mullett, Aman Khurana, Xitong Zhou, Garima Gupta, Daniel Flora, Colleen Darnell, Richard O'Neil, Charles Kunos, Mark B. Evers, Lowell Anthony, Susanne Arnold
Publikováno v:
Cancer Research. 83:CT221-CT221
Purpose: Immune checkpoint inhibitor (ICI) maintenance therapy is standard of care for frontline management of extensive stage small cell lung cancer (ES SCLC). However, overall survival benefit of addition of ICI maintenance to frontline ES SCLC tre
Autor:
Sani Kizilbash, David Piccioni, Solmaz Sahebjam, John Villano, Kurt Jaeckle, Mary Welch, Xiao-Tang Kong, Matthias Holdhoff, Anita Lammers, Adam Remick, Joel Reid, Jacob Allred, John Port, Ian Lanza, Samuel McBrayer, Charles Kunos, Geoffrey Shapiro, Alex Adjei
Publikováno v:
Neuro-Oncology. 24:vii75-vii75
IDH mutant gliomas depend on glutaminase for glutamate/glutathione generation from glutamine because R-2-hydroxyglutarate inhibits branched chain amino acid transaminase mediated glutamate biosynthesis. Telaglenastat (CB-839 HCl) is a potent glutamin
Autor:
Olivier Rixe, John Morris, Robert Wesolowski, Emrullah Yilmaz, John Villano, Carolyn Muller, Trisha Wise-Draper, Vinay Puduvalli, Richard Curry III, Ray Takigiku, Gilles Tapolsky
Publikováno v:
Neuro-Oncology. 24:i41-i41
The significance of a dysregulated sphingolipid metabolism in cancer, including brain tumors, has been demonstrated and several enzymes involved in sphingolipid metabolism are being investigated as novel therapeutic targets for adult and pediatric br
Autor:
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M O'Rourke, Mark Wong, Mark G Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D Turner, Michael J Yellin, Tibor Keler, Thomas A Davis, Roger Stupp, John H Sampson, Jian Campian, Lawrence Recht, Samuel Goldlust, Kevin Becker, Gene Barnett, Garth Nicholas, Annick Desjardins, Tara Benkers, Naveed Wagle, Morris Groves, Santosh Kesari, Zsolt Horvath, Ryan Merrell, Richard Curry, James O'Rourke, David Schuster, Maciej Mrugala, Randy Jensen, John Trusheim, Glenn Lesser, Karl Belanger, Andrew Sloan, Benjamin Purow, Karen Fink, Jeffrey Raizer, Michael Schulder, Suresh Nair, Scott Peak, Alba Brandes, Nimish Mohile, Joseph Landolfi, Jon Olson, Ross Jennens, Paul DeSouza, Bridget Robinson, Marka Crittenden, Kent Shih, Alexandra Flowers, Shirley Ong, Jennifer Connelly, Costas Hadjipanayis, Pierre Giglio, Frank Mott, David Mathieu, Nathalie Lessard, Sanchez Juan Sepulveda, József Lövey, Helen Wheeler, Po-Ling Inglis, Claire Hardie, Daniela Bota, Maciej Lesniak, Jana Portnow, Bruce Frankel, Larry Junck, Reid Thompson, Lawrence Berk, John McGhie, David Macdonald, Frank Saran, Riccardo Soffietti, Deborah Blumenthal, Sá Barreto Costa Marcos André de, Anna Nowak, Nimit Singhal, Andreas Hottinger, Andrea Schmid, Gordan Srkalovic, David Baskin, Camilo Fadul, Louis Nabors, Renato LaRocca, John Villano, Nina Paleologos, Petr Kavan, Marshall Pitz, Brian Thiessen, Ahmed Idbaih, Jean Sébastien Frenel, Julien Domont, Oliver Grauer, Peter Hau, Christine Marosi, Jan Sroubek, Elizabeth Hovey, P.S. Sridhar, Lawrence Cher, Erin Dunbar, Thomas Coyle, Jane Raymond, Kevin Barton, Michael Guarino, Sumul Raval, Baldassarre Stea, Jorge Dietrich, Kirsten Hopkins, Sara Erridge, Joachim-Peter Steinbach, Losada Estela Pineda, Quintero Carmen Balana, Barco Berron Sonia del, Miklós Wenczl, Katalin Molnár, Katalin Hideghéty, Alexander Lossos, Linde Myra van, Ana Levy, Rosemary Harrup, William Patterson, Zarnie Lwin, Sith Sathornsumetee, E-Jian Lee, Jih-Tsun Ho, Steven Emmons, J. Paul Duic, Spencer Shao, Hani Ashamalla, Michael Weaver, Jose Lutzky, Nicholas Avgeropoulos, Wahid Hanna, Mukund Nadipuram, Gary Cecchi, Robert O'Donnell, Susan Pannullo, Jennifer Carney, Mark Hamilton, Mary MacNeil, Ronald Beaney, Michel Fabbro, Oliver Schnell, Rainer Fietkau, Guenther Stockhammer, Bela Malinova, Karel Odrazka, Martin Sames, Gil Miguel Gil, Evangelia Razis, Konstantin Lavrenkov, Guillermo Castro, Francisco Ramirez, Clarissa Baldotto, Fabiana Viola, Suzana Malheiros, Jason Lickliter, Stanislaw Gauden, Arunee Dechaphunkul, Iyavut Thaipisuttikul, Ziad Thotathil, Hsin-I Ma, Wen-Yu Cheng, Chin-Hong Chang, Fernando Salas, Pierre-Yves Dietrich, Christoph Mamot, Lakshmi Nayak, Shona Nag
Publikováno v:
The Lancet Oncology, Vol. 18, No 10 (2017) pp. 1373-1385
The Lancet. Oncology, vol 18, iss 10
The Lancet. Oncology, vol 18, iss 10
Summary Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b6b5ae20a38597b1d233965368e0708
https://doi.org/10.5167/uzh-141081
https://doi.org/10.5167/uzh-141081